Ananata Pandit, MD
Internal Medicine · Chicago, ILNPI 1073826327
Payments from drug & device makers
Across 288 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$915
- Johnson & Johnson$541
- Novartis$537
- Amgen$509
- Pfizer$404
- AstraZeneca$394
- plus $3K from 25 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$5,92898%
- Education$1412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 44 | $915 |
| Johnson & Johnson | 23 | $541 |
| Novartis | 33 | $537 |
| Amgen(2 entities) | 29 | $509 |
| Pfizer | 17 | $404 |
| AstraZeneca | 23 | $394 |
| Bayer | 16 | $389 |
| Boehringer Ingelheim | 14 | $329 |
| Teva Pharmaceuticals USA, Inc. | 11 | $275 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $258 |
| AbbVie(2 entities) | 10 | $255 |
| Sunovion Pharmaceuticals Inc. | 7 | $168 |
| Amarin Pharma, Inc. | 3 | $166 |
| Regeneron Healthcare Solutions, Inc. | 1 | $134 |
| GSK | 6 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $101 |
| Merck | 5 | $90 |
| Exact Sciences | 4 | $77 |
| Hikma Pharmaceuticals USA | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Novo Nordisk | 3 | $55 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Philips North America LLC | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Braintree Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,068 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 243 | $157,493 |
| JardianceEmpagliflozin | 66 | $80,977 |
| TrulicityDulaglutide | 53 | $71,167 |
| MounjaroTirzepatide | 40 | $66,497 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $30,418 |
| LinzessLinaclotide | 27 | $24,660 |
| TradjentaLinagliptin | 22 | $24,230 |
| JanuviaSitagliptin Phosphate | 110 | $22,896 |
| XareltoRivaroxaban | 15 | $21,898 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $20,964 |
| EntrestoSacubitril/Valsartan | 20 | $17,441 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $16,604 |
| Spiriva RespimatTiotropium Bromide | 13 | $12,333 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $10,669 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 267 | $10,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $404 | $157,493243 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $915 | $137,66493 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $329 | $117,540101 claims |
| GSKBreo Ellipta, Incruse Ellipta, Trelegy Ellipta | $124 | $67,986128 claims |
| AbbVieLinzess | $255 | $24,66027 claims |
| MerckJanuvia | $90 | $22,896110 claims |
| Johnson & JohnsonXarelto | $541 | $21,89815 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $394 | $19,77045 claims |
| NovartisEntresto | $537 | $17,44120 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $58 | $2,05314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.